ChartMill · Aug 5, 2026
Geron (NASDAQ:GERN) Falls After Mixed Q2 Results; Revenue Beats but Loss Wider Than Expected
Geron's Q2 2026 results mixed: RYTELO revenue beats estimates, but wider adjusted loss and flat guidance weigh on shares.
GE
NASDAQ · GERN
Geron Corporation
Healthcare · Biotechnology
$1.49
Down-$0.02 (-1.32%)
Updated Sep 1, 2026, 8:41 AM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 884.12M
- P/E ratio
- -11.55
- Dividend yield
- 0.00%
- 52-week range
- $1.04 – $2.01
- Volume
- 7.25M
- Avg. volume
- 7.6M
Price performance
GERN price history
1M range · 21 trading sessions · Daily adjusted prices
GERN closed at $1.49 after 21 trading sessions, up 16.41% for the selected period.
- Last close
- $1.49
- Period change
- +16.41%
- Period low
- $1.28
- Period high
- $1.63
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 31, 2026 | $1.50 | $1.51 | $1.45 | $1.49 | 7.25M |
| Aug 28, 2026 | $1.53 | $1.53 | $1.49 | $1.51 | 7.42M |
| Aug 27, 2026 | $1.54 | $1.56 | $1.50 | $1.53 | 7.88M |
| Aug 26, 2026 | $1.58 | $1.58 | $1.50 | $1.53 | 9.12M |
| Aug 25, 2026 | $1.55 | $1.59 | $1.50 | $1.55 | 9.84M |
| Aug 24, 2026 | $1.53 | $1.55 | $1.44 | $1.52 | 13.11M |
| Aug 21, 2026 | $1.56 | $1.57 | $1.50 | $1.52 | 4.43M |
| Aug 20, 2026 | $1.58 | $1.59 | $1.54 | $1.55 | 5.99M |
| Aug 19, 2026 | $1.57 | $1.59 | $1.525 | $1.59 | 8.02M |
| Aug 18, 2026 | $1.52 | $1.559 | $1.51 | $1.53 | 4.24M |
| Aug 17, 2026 | $1.455 | $1.55 | $1.45 | $1.53 | 8.41M |
| Aug 14, 2026 | $1.53 | $1.5301 | $1.44 | $1.47 | 11.16M |
| Aug 13, 2026 | $1.58 | $1.60 | $1.525 | $1.535 | 5.63M |
| Aug 12, 2026 | $1.63 | $1.64 | $1.56 | $1.57 | 10.2M |
| Aug 11, 2026 | $1.50 | $1.65 | $1.47 | $1.63 | 12.72M |
| Aug 10, 2026 | $1.45 | $1.51 | $1.43 | $1.48 | 5.64M |
| Aug 7, 2026 | $1.565 | $1.605 | $1.46 | $1.48 | 8.89M |
| Aug 6, 2026 | $1.60 | $1.62 | $1.53 | $1.57 | 16.21M |
| Aug 5, 2026 | $1.37 | $1.63 | $1.3601 | $1.63 | 36.08M |
| Aug 4, 2026 | $1.32 | $1.36 | $1.31 | $1.34 | 13.46M |
| Aug 3, 2026 | $1.30 | $1.30 | $1.24 | $1.28 | 19.56M |
Latest GERN news
The latest Smart Investors Daily articles mentioning GERN.
Stock researchCompany · Overview
GERN research
Overview
Company profile and research snapshot.
Company profile
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $5.89
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 5, 2025 | Needham | Buy | — |
| Jul 10, 2025 | Goldman Sachs | Sell | — |
| May 8, 2025 | Scotiabank | Sector Perform | — |
| Mar 12, 2025 | HC Wainwright & Co. | Neutral | — |
| Mar 12, 2025 | Needham | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 5, 2026
Geron Corporation (GERN) Q2 2026 Earnings Call Transcript
Geron Corporation (GERN) Q2 2026 Earnings Call August 5, 2026 8:00 AM EDTCompany ParticipantsDawn Schottlandt - Senior Vice President of Investor Relations...
Yahoo · Jul 22, 2026
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective July 17, 2026, it granted stock options to purchase an aggregate of 202,500 shares of common stock to five newly hired employees as an inducement material to such employees’ acceptance of employment with Geron. The stock options have an exercise price of $1.44 per share, which is equal to the closing price of Geron’s common stock on
Yahoo · Jul 22, 2026
Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026
FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its second quarter 2026 financial results and business highlights before the market opens on Wednesday, August 5, 2026, via press release, which will be available on the Investors and Media section of the Company’s website. Geron will host a conference call and webc
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
